Objective:To observe the application effect of Wuguteng tablets in the treatment of acute myeloid leukemia (AML).Methods: A total of 60 patients with AML who were admitted in The First Affiliated Hospital of Kunming M...Objective:To observe the application effect of Wuguteng tablets in the treatment of acute myeloid leukemia (AML).Methods: A total of 60 patients with AML who were admitted in The First Affiliated Hospital of Kunming Medical University from March, 2015 to January, 2016 were included in the study and divided into the study group and the control group with 30 cases in each group according to different treatment protocols. The patients in the two groups were given routine chemotherapy regimens. On this basis, the patients in the study group were given additional Wuguteng tablets. ECOG value, blood routine examination results, and average transfusion interval before treatment and 2 months after treatment in the two groups were compared in order to estimate the therapeutic effect.Results:The comparison of WBC and Hb count after treatment between the two groups was not statistically significant (P>0.05). PLT count after treatment in the study group was significantly higher than that in the control group (P<0.05). ECOG and RBC average transfusion interval after treatment in the study group were not significantly different from those before treatment (P>0.05), while PLT average transfusion interval was significantly delayed when compared with before treatment (P<0.05). ECOG after treatment in the study group was significantly elevated (P<0.05), while PLT average transfusion interval was significantly reduced when compared with before treatment (P<0.05). ECOG after treatment in the study group was significantly lower than that in the control group (P<0.05), while PLT average transfusion interval was significantly delayed when compared with the control group (P<0.05).Conclusions:Wuguteng tablets in the adjuvant treatment of AML can significantly delay PLT average transfusion interval, increase PLT, and improve the clinical symptoms;therefore, it deserves to be widely recommended in the clinic.展开更多
文摘Objective:To observe the application effect of Wuguteng tablets in the treatment of acute myeloid leukemia (AML).Methods: A total of 60 patients with AML who were admitted in The First Affiliated Hospital of Kunming Medical University from March, 2015 to January, 2016 were included in the study and divided into the study group and the control group with 30 cases in each group according to different treatment protocols. The patients in the two groups were given routine chemotherapy regimens. On this basis, the patients in the study group were given additional Wuguteng tablets. ECOG value, blood routine examination results, and average transfusion interval before treatment and 2 months after treatment in the two groups were compared in order to estimate the therapeutic effect.Results:The comparison of WBC and Hb count after treatment between the two groups was not statistically significant (P>0.05). PLT count after treatment in the study group was significantly higher than that in the control group (P<0.05). ECOG and RBC average transfusion interval after treatment in the study group were not significantly different from those before treatment (P>0.05), while PLT average transfusion interval was significantly delayed when compared with before treatment (P<0.05). ECOG after treatment in the study group was significantly elevated (P<0.05), while PLT average transfusion interval was significantly reduced when compared with before treatment (P<0.05). ECOG after treatment in the study group was significantly lower than that in the control group (P<0.05), while PLT average transfusion interval was significantly delayed when compared with the control group (P<0.05).Conclusions:Wuguteng tablets in the adjuvant treatment of AML can significantly delay PLT average transfusion interval, increase PLT, and improve the clinical symptoms;therefore, it deserves to be widely recommended in the clinic.
